IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#2968
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$355M
Rick J. Pauls
DiaMedica Therapeutics Inc. develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein. DM199 is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$DMAC DiaMedica Therapeutics Inc. | 44 | 28 | 43 | 65 | - | - | -58.7% | -53.1% | - | - | - | - | 0.0% | 11.0x | $355M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
DiaMedica Therapeutics Inc. (DMAC) receives a "Reduce" rating with a composite score of 44.0/100. It ranks #2968 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Rick J. Pauls
Chief Executive Officer
Labor Force
20
28
25
45
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for DMAC
Outperforming peers — winners tend to keep winning over 3-12 months
Fair valuation relative to peers
Weak fundamentals — higher risk of value trap
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for DMAC.
View All RatingsInsufficient data for Financial Analysis
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 28 | 7 | +21ALPHA |
| MOMENTUM | 65 | 62 | +3NEUTRAL |
| VALUATION | 43 | 21 | +22ALPHA |
| INVESTMENT | 25 | 13 | +12ALPHA |
| STABILITY | 45 | 25 | +20ALPHA |
| SHORT INT | 26 | 11 | +15ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -58.7% (sector -2.5%)
GM N/A vs sector 43%, OM N/A vs sector 1%
Capital turnover N/A
Rev growth N/A, 7yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
DiaMedica Therapeutics Inc. receives a Reduce rating from our analysis, with a composite score of 44.0/100 and 2 out of 5 stars, ranking #2968 out of 7,333 stocks. DMAC's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
DMAC's quality score of 28/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -58.7% (sector avg: -2.5%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 43/100, DMAC appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 8.49x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
DiaMedica Therapeutics Inc.'s investment score of 25/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -53.1% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
DMAC demonstrates moderate momentum with a score of 65/100, suggesting a neutral price trend without strong directional conviction. Revenue growth data is not currently available, while a beta of 1.48 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
With a stability score of 45/100, DMAC exhibits average financial resilience. Key stability metrics include a beta of 1.48 and a debt-to-equity ratio of 11.00x (sector avg: 0.2x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
DiaMedica Therapeutics Inc.'s short interest score of 26/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include above-average market sensitivity (beta: 1.48), elevated leverage (D/E: 11.00x), small-cap liquidity risk. At $355M (small-cap), DMAC carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
DiaMedica Therapeutics Inc. is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #2968 of 7,333 overall (60th percentile). Key comparisons include ROE of -58.7% trailing the -2.5% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While DMAC currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Investment (25) would have the largest impact on the composite score.
ROE 2267% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 5400% ABOVE SECTOR MEDIAN
Div. Yield NaN% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate DiaMedica Therapeutics Inc. (DMAC) as a Reduce with a composite score of 44.0/100 at a current price of $8.55. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential and elevated risk of underperformance relative to peers over the next 12 months.
The rating is primarily driven by strength in momentum (65th percentile) and stability (45th percentile), which together account for the majority of the composite score. Offsetting weakness in investment (25th percentile) and quality (28th percentile) tempers our overall conviction. We assign a No Moat rating (18/100), High uncertainty, and Poor capital allocation.
Key items to watch: quarterly earnings execution and sector-level competitive dynamics. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
DiaMedica Therapeutics Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 44.0/100 places it at rank #2968 in our full 7,333-stock universe. At $355M in market capitalization, DiaMedica Therapeutics Inc. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Momentum indicators (65th percentile) are constructive regarding the near-term price trend. Revenue growth data is unavailable, limiting our ability to confirm whether momentum is fundamentally supported.
Margin data is not available for DiaMedica Therapeutics Inc., which limits our assessment of the company's cost structure and operating efficiency. We rely on factor-based signals to infer business quality in the absence of detailed margin data.
At a current price of $8.55, DiaMedica Therapeutics Inc. is trading near fair value based on current fundamentals. Our value factor score of 43/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. Valuation metrics are mixed, with no strong signal of mispricing in either direction.
The stock currently trades at P/B of 8.5x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
A conservative balance sheet (11% D/E) provides financial flexibility for acquisitions, buybacks, or weathering economic downturns without dilution.
The Reduce rating (composite 44.0/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Below-average quality (28th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
High beta of 1.48 means amplified losses in market selloffs — in a broad market correction, this stock would likely decline more than the index.
We assign a High uncertainty rating to DiaMedica Therapeutics Inc.. Key risk factors include elevated market sensitivity (beta of 1.48), weak quality scores (28th percentile). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: elevated market sensitivity (beta of 1.48); weak quality scores (28th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 45th percentile and quality factor at the 28th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: conservative leverage (11% D/E) limits balance sheet risk. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate DiaMedica Therapeutics Inc.'s capital allocation as Poor. Key concerns include low returns on equity (-58.7%), weak asset returns (ROA -53.1%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — DiaMedica Therapeutics Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, DiaMedica Therapeutics Inc. receives a Reduce rating with a composite score of 44.0/100 (rank #2968 of 7,333). Our quantitative framework assigns a No Moat (18/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 41/100.
Our analysis does not support a constructive view on DiaMedica Therapeutics Inc. at this time. The combination of limited competitive advantages, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign DiaMedica Therapeutics Inc. a meaningful economic moat, scoring 18/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 10/20.
The strongest moat sources are margin superiority (10/20) and financial resilience (6.6/20). GM N/A vs sector 43%, OM N/A vs sector 1%. Interest coverage N/A. These pillars form the core of DiaMedica Therapeutics Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (0/20) and reinvestment efficiency (0/20). ROE proxy -58.7% (sector -2.5%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect DiaMedica Therapeutics Inc.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers are not clearly identifiable from current fundamentals. This may reflect a company in transition, a cyclical downturn, or structural challenges in the business model. We assign a quality factor of 28/100 which further underscores our concern regarding earnings sustainability.
Return metrics include ROE of -58.7% and ROA of -53.1%. Relative to the Manufacturing sector, sector comparison data is limited, and ROE of -58.7% compares to a sector median of -2.5%.
The balance sheet reflects a conservatively managed balance sheet with D/E of 11%. The sector median D/E is 0%, putting DiaMedica Therapeutics Inc. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Above 50MA
37.18%
Net New Highs
+51081
MINNEAPOLIS, February 24, 2026--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that company management will participate in three upcoming investment bank conferences.
Key Insights Insiders appear to have a vested interest in DiaMedica Therapeutics' growth, as seen by their sizeable...
MINNEAPOLIS, January 16, 2026--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that on January 15, 2026, it granted options to purchase an aggregate of 50,000 shares of DiaMedica’s common stock to a newly hired non-executive employee whose employment commenced in December 2025. The stock options were a material inducement to the emplo
MINNEAPOLIS, December 18, 2025--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS), today announced completion of a productive in-person pre-IND meeting with the United States Food and Drug Administration (FDA) for a planned study evaluating DM199 in preeclampsia. Minutes from the meeting affirmed the FDA’s request for one additional non-clinical,
Upgrades For DiaMedica Therapeutics Inc (NASDAQ:DMAC), Oppenheimer upgraded the previous rating of Perform to Outperform. In the first quarter, DiaMedica Therapeutics showed an EPS of $0.20, compared to $0.13 from the year-ago quarter. At the moment, the stock has a 52-week-high of $4.05 and a 52-week-low of $1.12. DiaMedica Therapeutics closed at $3.64 at the end of the last trading period. For Kellogg Co (NYSE:K), Bernstein upgraded the previous rating of Underperform to Market Perform. For the first quarter, Kellogg had an EPS of $1.10, compared to year-ago quarter EPS of $1.10. At the moment, the stock has a 52-week-high of $77.16 and a 52-week-low of $63.74. Kellogg closed at $65.24 at the end of the last trading period. For Agree Realty Corp (NYSE:ADC), Mizuho upgraded the previous rating of Neutral to Buy. Agree Realty earned $0.98 in the first quarter, compared to $0.97 in the year-ago quarter. At the moment, the stock has a 52-week-high of $80.41 and a 52-week-low of $63.34. Agree Realty closed at $65.19 at the end of the last trading period. For Grab Holdings Inc (NASDAQ:GRAB), JP Morgan upgraded the previous rating of Underweight to Neutral. In the first quarter, Grab Hldgs showed an EPS of $0.06, compared to $0.11 from the year-ago quarter. At the moment, the stock has a 52-week-high of $4.03 and a 52-week-low of $2.19. Grab Hldgs closed at $3.39 at the end of the last trading period. For XP Inc (NASDAQ:XP), B of A Securities upgraded the previous rating of Neutral to Buy. For the first quarter, XP had an EPS of $0.28, compared to year-ago quarter EPS of $0.28. The current stock performance of XP shows a 52-week-high of $25.18 and a 52-week-low of $10.30. Moreover, at the end of the last trading period, the closing price was at $24.52. See all analyst ratings upgrades. Downgrades For Dow Inc (NYSE:DOW), B of A Securities downgraded the previous rating of Neutral to Underperform. For the first quarter, Dow had an EPS of $0.58, compared to year-ago quarter EPS of $2.34. At the moment, the stock has a 52-week-high of $60.88 and a 52-week-low of $42.92. Dow closed at $51.88 at the end of the last trading period. For The AES Corp (NYSE:AES), B of A Securities downgraded the previous rating of Buy to Neutral. In the first quarter, AES showed an EPS of $0.22, compared to $0.21 from the year-ago quarter. The current stock performance of AES shows a 52-week-high of $29.87 and a 52-week-low of $18.91. Moreover, at the end of the last trading period, the closing price was at $20.98. For Celanese Corp (NYSE:CE), B of A Securities downgraded the previous rating of Buy to Neutral. Celanese earned $2.01 in the first quarter, compared to $5.54 in the year-ago quarter. The stock has a 52-week-high of $128.35 and a 52-week-low of $86.73. At the end of the last trading period, Celanese closed at $108.52. For The Chemours Co (NYSE:CC), B of A Securities downgraded the previous rating of Buy to Neutral. Chemours earned $0.98 in the first quarter, compared to $1.46 in the year-ago quarter. The stock has a 52-week-high of $38.34 and a 52-week-low of $23.60. At the end of the last trading period, Chemours closed at $33.95. For Enphase Energy Inc (NASDAQ:ENPH), OTR Global downgraded the previous rating of Mixed to Negative. For the first quarter, Enphase Energy had an EPS of $1.37, compared to year-ago quarter EPS of $0.79. At the moment, the stock has a 52-week-high of $339.88 and a 52-week-low of $152.15. Enphase Energy closed at $167.99 at the end of the last trading period. According to BMO Capital, the prior rating for Xcel Energy Inc (NASDAQ:XEL) was changed from Outperform to Market Perform. Xcel Energy earned $0.76 in the first quarter, compared to $0.70 in the year-ago quarter. At the moment, the stock has a 52-week-high of $77.63 and a 52-week-low of $56.92. Xcel Energy closed at $62.81 at the end of the last trading period. According to Oppenheimer, the prior rating for Equinix Inc (NASDAQ:EQIX) was changed from Outperform to Perform. For the first quarter, Equinix had an EPS of $8.59, compared to year-ago quarter EPS of $7.16. The current stock performance of Equinix shows a 52-week-high of $792.02 and a 52-week-low of $495.11. Moreover, at the end of the last trading period, the closing price was at $768.00. According to Morgan Stanley, the prior rating for Tesla Inc (NASDAQ:TSLA) was changed from Overweight to Equal-Weight. In the first quarter, Tesla showed ...Full story available on Benzinga.com